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25. Drugs affecting blood 
25.1 Introduction 
The circulatory system has a number of important physiological functions. These include 
transport of metabolites, hormonal and temperature regulation and protection against disease. 
All of the molecules needed for normal cellular metabolism are transported in the blood. Red 
blood cells carry oxygen to tissues and remove carbon dioxide waste gases. In addition, the 
blood carries nutrients from digestion and absorption of foodstuffs to target cells and removes 
excess water and unwanted waste products of cellular metabolism to the kidney for excretion. 
Blood also transports hormones and other cellular control molecules from site of synthesis to 
their site of action and is involved in body temperature regulation. Furthermore the 
circulatory system aids in protection against foreign invasion by toxin or bacteria through 
protective white blood cells (leukocytes), whilst clotting mechanisms protect against blood 
loss when the blood vessels of the circulatory system are damaged. 
Blood comprises two portions, a cellular component termed the “formed elements” and a 
“fluid component” termed plasma. The plasma is a pale yellow fluid that consists of water, 
dissolved solutes, soluble metabolites, hormones, antibodies and other proteins including the 
albumins and globulins which are used to transport molecules around the body and 
fibrinogen, which is an important clotting factor. Within the “formed elements” are the 
cellular components of blood including the erythrocytes (used to transport oxygen via 
haemoglobin), platelets (involved in blood clotting) and the leukocytes (which comprise 
neutrophils, eosinophils, basophils, monocytes and lymphocytes and whose roles include 
phagocytosis and the release of antibodies as an immune response). 
25.2 Important dysfunctions of the blood system 
There are a number of pathophysiological conditions associated with dysfunctions of the 
circulatory system (see Figure at end of this eChapter). The major problems are thrombosis 
(the formation of an unwanted clot within the blood vessels or heart), uncontrolled bleeding 
(as a result of a disease or injury) and anaemia (caused by disease or nutritional deficiencies). 
Other problems that can arise include cancers associated with components of the circulatory 
system (for  example, leukaemia, lymphoma), diseases resulting in reduced or increased 
functioning of the immune system (rheumatoid arthritis, systemic lupus) and 
hyperlipidaemias. These are covered elsewhere. 
 
25.3 Drugs used in to correct dysfunctions of the blood 
25.3.1 Anti-thrombosis treatments 
Thrombosis occurs when there is formation of an unwanted blood clot (thrombus) or 
movement of an existing clot to a location where it can block important blood vessels. When 
there is damage to a blood vessel, a number of co-ordinated processes occur, resulting in the 
formation of a fibrin-platelet thrombus plug that facilitates cessation of bleeding 
(haemostasis) at the site of injury. This process includes movement of platelets to the site of 
injury and their adhesion to, and covering of, the exposed collagen of the subendothelial 
tissues via binding to von Willebrand factor and glycoprotein Ib (GpIb). The platelets then 
become active and release a variety of chemoattractants including ADP, thromboxane A2, 
serotonin and platelet activating factor (PAF) which in turn mobilise other platelets to the site 
of injury where they begin to adhere and aggregate into the growing clot via GpIIb/IIIa 
platelet receptors. Fibrinogen, a soluble plasma protein, simultaneously binds to GpIIb/IIIa 
receptors on two separate platelets resulting in platelet crosslinking and further platelet 
aggregation. Activation of the clotting cascade ultimately results in thrombin production from 
its precursor prothrombin. Thrombin, in turn, converts fibrinogen in the growing thrombus to 
fibrin, consolidating and stabilising the platelet plug.  
 
There are three drug treatments used to prevent formation of clots or to dissolve established 
thrombi. These are the anti-platelet drugs, the anticoagulents and the thrombolytics. 
 
25.3.1.1 Platelet aggregation inhibitors 
The anti-platelet drugs (or platelet aggregation inhibitors) work by decreasing the 
synthesis, release or action of the chemical molecules that promote platelet aggregation 
preventing clot formation. Aspirin inhibits cyclooxygenase-1 (COX-1), the enzyme 
responsible for the production of thromboxane A2 from arachidonic acid, thus blocking the 
synthesis of the aggregating agent. The main adverse effects of aspirin administration are 
gastrointestinal ulcers, stomach bleeding and tinnitus.  
 
Another drug which targets thromboxane A2 synthesis is dipyridamole which is a cyclic 
nucleotide phosphodiesterase inhibitor. Dipyridamole increases intracellular cyclic AMP 
levels which results in decreased thromboxane A2 synthesis. This agent is usually given in 
combination with aspirin or warfarin.  
 
Clopidogrel is approved for the prevention of atherosclerotic events following recent 
myocardial infarction, stroke or established peripheral vascular disease. Clopidogrel 
selectively inhibits the binding of ADP to its platelet receptor, an event that leads to 
inhibition of platelet aggregation by blocking activation of the GpIIb/IIIa pathway.  
 
Working in a similar way, abciximab is a monoclonal antibody that is indicated for 
percutaneous coronary intervention (angioplasty). It binds to the platelet GpIIb/IIIa receptor, 
preventing binding of von Willebrand factor, fibrinogen, and other adhesion molecules 
inhibiting receptor-mediated platelet activation and subsequent thrombus formation. The 
major adverse effect is potential for bleeding.  
Eptifibatide and tirofiban have similar indications, adverse reactions and mechanisms of 
action to abciximab except that they are not antibodies but chemical antagonists of the 
GpIIb/IIIa receptor.  
25.3.1.2 Anticoagulants 
The second group of antithrombosis drugs are the anticoagulants. In the process of forming 
a thrombus, fibrinogen is converted to fibrin by thrombin, the end point of the clotting 
cascade. The cascade is a series of reactions that sequentially transform various plasma 
fractions to their active enzymic form. They ultimately produce activated clotting factor Xa 
which converts prothrombin to thrombin. Anticoagulants exert their action by reducing the 
action of specific clotting factors, as in the case of the heparins, or by interfering with clotting 
factor synthesis, as demonstrated by the vitamin K antagonists.  
 
Heparin and its lower molecular weight forms (enoxaparin, dalteparin) exert their effects 
by binding to and activating antithrombin III. Activation of this enzyme results in thrombin 
inactivation and subsequent blocking of clot formation. These drugs are indicated for deep 
vein thrombosis, pulmonary embolism and acute coronary syndrome. Adverse effects of the 
heparins include haemhorrage and thrombocytopaenia.  
 
The coumarin anticoagulants (warfarin) exert their actions by inhibiting the synthesis of 
vitamin K dependent coagulation factors (VII, IX, X, II) perturbing the clotting cascade. 
They are used to prevent the progression or recurrence of deep vein thrombosis and 
pulmonary embolism. The main adverse reaction to warfarin treatment is haemorrhage. 
Warfarin has numerous drug interactions that may potentiate or attenuate its actions. As such 
warfarin administration should be monitored closely. 
 
25.3.1.3 Thrombolytics 
The last group of antithrombosis drugs are the thrombolytics (fibrinolytics). These drugs are 
used to dissolve clots that have already formed. They are usually administered intravenously 
to clear a blocked blood vessel (for example in coronary thrombosis) and work by promoting 
the conversion of plasminogen to plasmin, a serine protease enzyme that hydrolyses fibrin, 
dissolving the clot, allowing reperfusion to occur.  
 
The first drug in this class to be used was streptokinase, a protein isolated from beta-
haemolytic Streptococci. Streptokinase activates plasminogen and promotes its conversion to 
plasmin. However, streptokinase causes a systemic fibrinolytic effect that can lead to 
bleeding problems and this agent has been replaced by tissue-type plasminogen activators 
(tPAs) such as alteplase, tenecteplase and reteplase.  These agents have been produced by 
recombinant DNA technology and work locally on the thrombotic fibrin to produce 
fibrinolysis. Bleeding complications including gastrointestinal haemorrhage and stroke have 
been shown to occur with their use. 
  
25.3.2 Treatments for anaemia 
Anaemia is a condition where there is decreased plasma haemoglobin levels resulting from 
either a decreased number of circulating red blood cells or a deficiency of functioning 
haemoglobin within the erythrocytes themselves. This impacts on the capacity of the red 
blood cells to transport oxygen and nutrients to target tissues. There are a number of different 
types of anaemias, each characterised by the condition of their red blood cells. In microcytic 
anaemias (iron deficiency, sideroblastic anaemia) the erythrocytes are smaller than normal ;: 
in normocytic anaemia (bone marrow failure, endocrine anaemia), cells are normal sized; in 
macrocytic anaemia (pernicious anaemia, folic acid deficiency, megaloblastic anaemia), cells 
are larger than normal; whilst in haemolytic anaemia (haemaglobinopathies, infections), the 
cells have autolysed. All of these anaemic states cause similar symptoms such as pallor, 
shortness of breath and fatigue.   
 
Normal erythropoeisis requires a number of factors such as iron, vitamin B12 and folic acid, 
and a deficiency in any of these can cause anaemia. The main therapeutic approach to treating 
anaemia relies on replacing such deficiencies.  
 
Iron deficiency is a common cause of anaemia and can result from chronic blood loss (e.g. 
menorrhagia (heavy blood loss during menstrual periods)), from gut abnormalities resulting 
in reduced iron absorption and in heavily menstruating or pregnant women. Iron deficiency 
syndromes can be treated with oral or parental iron salt (ferrous sulphate, ferrous 
gluconate, ferrous glycine sulphate) supplementation. Gastrointestinal disturbances, 
particularly constipation are the most common side effects of these treatments.  
 
Vitamin B12 deficiency, either as a result of poor absorption of the vitamin itself or more 
commonly, failure to produce the intrinsic factor needed for vitamin B12 function, results in 
megaloblastic and pernicious anaemias. Treatment is by administration of various 
colbalamins (methylcobalamin, cyanocobalamin, hydroxocobalamin) which are 
chemically related forms of vitamin B12.  
 
Folic acid is required for DNA and amino acid synthesis. Deficiency can be caused by 
increased folate demand during pregnancy and lactation, poor absorption caused by disease 
of the small intestine, alcoholism or concomitant treatment with folate inhibitor drugs such as 
methotrexate.  Folica acid deficiencyleads to megaloblastic anaemia. Treatment is by oral 
folic acid administration.  
Erythropoietin is a glycoprotein hormone, produced in the kidney, that regulates red blood 
cell proliferation and differentiation in the bone marrow.  Recombinant human erythropoietin 
and darbepoetin, a variant with a longer half-life, are used to treat anaemias resulting from 
chronic kidney disease and from some chemotherapy treatments, particularly the platinum-
containing anticancer drugs.  
Sickle cell anaemia is a hereditary disorder in which a point mutation in one haemoglobin 
chains results in a valine being substituted for a glutamic acid. This haemoglobin, HbS, 
becomes sickle shaped when oxygenated resulting in impaired erythrocyte function. 
Treatment is with hydroxyurea which activates production of foetal haemoglobin, a process 
that occurs over many months, diluting the abnormal HbS.     
25.3.3 Treatments for bleeding disorders 
Uncontrolled bleeding occurs as a consequence of either a hereditary disease (haemophilia A, 
haemophilia B, von Willebrand’s disease) or an acquired condition (vitamin K deficiency, 
thrombocytopaenia, fibrinolysis after surgery).  
Hereditary bleeding disorders 
Haemophilic disease occurs as a result of a genetic lesion affecting one or more factors in the 
clotting cascade. Previous treatments involved administration of concentrated preparations of 
these factors isolated from donated human blood, a practice used less today with the ability of 
recombinant DNA technology to produce large amount of these components. Thus 
haemophilia A is treated with administration of clotting factor VIII and haemophilia B with 
clotting factor IX.   
 
Acquired bleeding disorders 
Treatment of acquired, uncontrolled bleeding is more problematical. In general, these 
episodes are caused by an individual being in a fibrinolytic state and treatment negates the 
cause of bleeding or potentiates the clotting mechanism.  
 
Vitamin K1 administration promotes the formation of various clotting factors (II, VI, IX, X) 
and can reverse an abnormal coagulation status (for example treatment after surgery) or 
bleeding due to vitamin K1 deficiency.  
 
Protamine sulphate is a heparin antagonist and is used to counteract the effect of this drug 
before and after surgery.  
 
Tranexamic acid is a competitive inhibitor of the plasminogen activation process resulting in 
decreased production of plasmin and subsequent plasmin-mediated fibrinolysis. It is used to 
treat menorrhagia and patients with clotting disorders undergoing surgery.  However, a 
potential side effect of treatment with tranexamic acid is intravascular thrombosis.  
 
Similarly, aprotinin a serine protease used to reduce perioperative blood loss, also stops 
bleeding by blocking the action of plasmin.  
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